ATP News Events Archive
|Advanced Technology Research Facility Occupancy: With the ATP administration offices having moved into the ATRF, the ATP laboratories have started the relocation process. To see when each laboratory is estimated to be up and running again, please see the individual laboratory websites.
Hoyt Matthai, ATP’s Operations Director on the project, can be contacted for further details.
|In the latest issue of the Dossier, the work of Dr. Anu Puri from the Nanobiology Program (CCR, NCI) is highlighted along with her successful interaction with the Protein Chemistry Laboratory (PCL) and the Laboratory of Proteomics and Analytical Technologies (LPAT). Drs. Simona Colantonio and Jack Simpson (PCL) developed an assay to quantitate the levels of lipids using NALDI (nanostructured assisted laser/desorption and ionization)-TOF technology. Drs. Timothy Veenstra and Athar Masood (LPAT) utilized a different approach to quantitate the ratios of lipids and the degradation products following photoactivation by light. The lipid analysis was performed using the LC-MS and quantitated using the selected reaction monitoring.|
|The TRG Update (PDF, 5.1 MB): ATP is part of the Technology and Research Group (TRG), which comprises five directorates that employ advanced biomedical technologies in support of the mission of the National Cancer Institute. In the most recent TRG quarterly newsletter, Dr. Dave Heimbrook, ad interim chief technology officer, explains the ad interim reporting structure within TRG as well as ATP, and addresses the impact of the continued reduction of the cost of genome sequencing. Also in this issue: Personal Genome Machine Sequences without Light, at Extraordinary Speed; Collaboration with FDA Probes Sterilization Effects on Silver Nanoparticles; Developing an Accurate Method to Measure Sarcosine, a Potential Biomarker for Prostate Cancer; Novel Treatment for MCD Results in 86 Percent of Patients Attaining Major Clinical Responses; PHL/LASP and Biomatrica Partner to Improve Quality of DNA, RNA Testing; Administration Wing, Atrium Construction to Begin in the Fall; Genetics Core Provides Dedicated Support to CCR;Cryopreservation: Less Risk and Lower Cost in Colony Management; Congratulations to Our Outstanding Contributors|
Laboratory of Proteomics and Analytical Technologies (LPAT) scientists, Steve Fox and Haleem Issaq in collaboration with DCEG investigators recently conducted a study that was highlighted in a recent edition of Chemical and Engineering News. This article highlighted their development of an assay to measure sarcosine, a potential diagnostic marker of advancing prostate cancer, in clinical samples. Studies evaluating sarcosine as a biomarker have given conflicting studies prompting Steve and Haleem to speculate that some studies may have been measuring a combination of sarcosine and its structural isomers, α- and β-alanine. Indeed, when they replicated a previously reported study, they were able to show that a combination of three molecules was being mistaken for sarcosine. For more information, click here.
SAIC-Frederick, Inc. and RemedyMD, Inc. Collaborate to Enhance Research Management Systems in Support of Cancer Research. FREDERICK, MD. August 23, 2011 — SAIC-Frederick Inc. and RemedyMD, Inc. announced today an agreement to implement RemedyMD’s Investigate™ Integrated Research Management System software at the National Cancer Institute (NCI) Advanced Technology Program in Frederick, Md. The software is designed to help manage and analyze large amounts of research data to accelerate progress against cancer. For more information, click here.
|ATP scientist, Dr. Deb Chatterjee was a featured speaker to the Frederick Chamber of Commerce event: Tech-Connect. Dr. Chatterjee’s presentation focused on development of a Virus-Like Particle (VLP) platform for protein and gene delivery that was pioneered in the Protein Expression Laboratory. For more information, click here.|
|The Laboratory of Proteomics and Analytical Technologies (LPAT) recently installed a Tecan robot that greatly minimizes hands-on time, allowing scientists to focus on data analysis and method development instead of repetitive laboratory procedures. The scientists at LPAT are also working in conjunction with Tecan engineers to help develop an automated system for analyzing estrogen metabolites. For more information, click here.|
|Cutting Edge Sequencing Technologies in Development at the ATP: Early on the ATP recognized the impact that next and 3rd generation sequencing technologies will have on genomics and medicine. A commitment has been made to stay ‘ahead of the curve’ with respect to acquisition and implementation of these cutting edge technologies and the development of applications that maximize their utility. The ATP is an early access partner with Pacific Biosciences and has recently acquired an Ion Torrent sequencer. For further information or access to these platforms please contact Dr. David Munroe, Director of Technology Development at the ATP.|
|NEW! Biomarkers identified by the Laboratory of Proteomics and Analytical Technologies (LPAT) and the NCI: Development of blood-based protein biomarkers that are diagnostic of cancer have yet to be validated on larger patient cohort and applied in clinical settings. The LPAT assists NCI researchers in identifying biomarkers and developing robust, specific, and quantitative mass spectrometry assays. Dr. Josip Blonder’s clinical biomarker development work in the LPAT has been highlighted in a recent issue of Genetic Engineering & Biotechnology News (GEN). For more information on this discovery and an associated article in Analytical Chemistry, please view the LPAT What’s New page.|
|Genetics and Genomics Company Showcase featuring Illumina, Life Technologies, Affymetrix and Fluidigm. June 1st, 10:00 to 3:00, Building 549, NCI-Frederick. More details about the agenda HERE. For questions, please contact Dr. Michael Smith (301-846-1913).|
|TECHNOLOGY SEMINAR: RainDance Technologies, Microdroplet-based PCR Amplification: Sequence Enrichment for Oncology ApplicationsWednesday, April 13th, 10:00 am – 11:00 am, Building 426, Conference Room Seminar Speaker: Jim Brayer, Senior Product Manager for Target Enrichment.|
|NEW! Josip Blonder of the Laboratory of Proteomics and Analytical Technologies (LPAT) was featured in the Center for Cancer Research (CCR), Staff Scientist and Staff Clinician publication, The Dossier. The article features ongoing technology development within the LPAT in the area of targeted clinical proteomics towards cancer biomarker discovery. To see what’s new in the LPAT, please click here.|
|Plasmids from the Protein Expression Laboratory (PEL) Facilitate NCI Research: Dr. Alex Wlodawer’s Macromolecular Crystallography Laboratory solved the structure of the protease from Xenotropic murine leukemia virus-related virus (XMRV) using clones produced by the PEL. The data appears in the February issue of Nature Structural Biology. “Access to these clones,” said Dr. Wlodawer, “sped up the project by months.” MORE|
|Lentiviral Vector Panel The Protein Expression Laboratory developed a panel of lentiviral expression clones and lentivirus particles for use in determining the optimal promoter for your experiments and cell lines. We have found that optimization of promoter for your particular cell type and application can have a dramatic effect on the results of your experiments (see Day C-P, et al., Pig. Cell. Melanoma Res. 2009; 22(3): 283-95)|
|Advances in Live Cell Imaging: Olympus Confocal & Incubator Microscope Workshop, Februray 8-18 2011: The Optical Microscopy and Analysis Laboratory (OMAL) continually reviews and tests the latest technology advances in microscopy. OMAL is sponsoring a technical demonstration of live-cell confocal imaging coupled to climate controlled incubation on February 8th, 2011. Registration is not required for the February 8th afternoon seminars. However, you will need to sign up in advance for time on one of the instruments that will be housed in the OMAL from February 8-18. Please contact Dr. Stephen J. Lockett or one of the Olympus personnel who are assisting with the workshop.|
|The Advanced Technology Program Launches a New Web Site: http://ncifrederick.cancer.gov
Members of the ATP program will continually update the web site content. Each ATP laboratory is represented on the the new web site with specific pages dedicated to:
Services: Core services available on a fee-for-service basis
Protocols and Resources: Helpful documents from the laboratories
Technology Development: New technologies being explored by the laboratories
What’s New: Recent publications describing collaborative work with NCI scientists
Staff Directory: Providing contact information of program scientists
|Ft. Detrick Campus Technology Symposium The Advanced Technology Program, in conjunction with the National Interagency Confederation for Biological Research (NICBR) hosted the Ft. Detrick Campus Technology Symposium. The event focused on Imaging and Probe Development, Telemetry, and “Omics” and Assay Development, and brought together the NICBR partners including NCI, NIAID, NRL, NBACC, USAMRIID and USDA. Speakers from the ATP included, Drs. Tim Veenstra, Stephen Lockett, Ulrich Baxa, Scott McNeil and Jack Simpson.|